Teprotumumab for the Treatment of Active Thyroid Eye Disease

Douglas, RS; Kahaly, GJ; Patel, A; Sile, S; Thompson, EHZ; Perdok, R; Fleming, JC; Fowler, BT; Marcocci, C; Marino, M; Antonelli, A; Dailey, R; Harris, GJ; Eckstein, A; Schiffman, J; Tang, R; Nelson, C; Salvi, M; Wester, S; Sherman, JW; Vescio, T; Holt, RJ; Smith, TJ

Douglas, RS (corresponding author), Cedars Sinai Med Ctr, W Med Off Towers,8635 W Third St,Suite 650W, Los Angeles, CA 90048 USA.

NEW ENGLAND JOURNAL OF MEDICINE, 2020; 382 (4): 341

Abstract

Background Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition for which no Food and Drug Administration......

Full Text Link